Trastutzumab duocarmazine has shown preclinical antitumor activity in HER2-expressing epithelial ovarian carcinoma, uterine serous carcinoma, and uterine and ovarian carcinosarcomas [44,45,46]. The gene discussed is ERBB2; the disease is endometrial serous adenocarcinoma.